{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:49:44Z","timestamp":1781887784882,"version":"3.54.5"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2020-0447_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study was conducted to assess adverse drug reactions and their management in MDR-TB patients. Indonesia is the fifth highest country with multidrug-resistant tuberculosis (MDR-TB) high burden around the world. The number of MDR-TB patients in Indonesia is increasing every year, but the data regarding ADRs are still limited. Therefore, more data on their characteristics and their management is very valuable for clinicians and pharmacists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0447_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a descriptive study, using retrospective data of MDR-TB patients who completed therapy from January 1st, 2015 to December 31st, 2015 at the Tuberculosis Outpatient unit at the Dr. Soetomo Teaching Hospital Indonesia. Each adverse effect was judged with standards of the clinic and was documented in patients\u2019 medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0447_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 40 patients included in this study. During therapy, 70% of patients developed at least one adverse drug reaction. The five most prevalent adverse effects found in this study were hyperuricemia (52.5%) followed by gastrointestinal (GI) disturbances (40%), ototoxicity (37.5%), hypokalemia (27.5%), and athralgia (12.5%). Managements that were undertaken to overcome the adverse drug reactions were adding symptomatic drugs and\/or modifying the treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2020-0447_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Because of the small samples we cannot attain a general conclusion. However, the result of this study is very imperative as this data gives us insight regarding adverse effects in MDR-TB patients in Indonesia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2020-0447","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T14:31:11Z","timestamp":1625236271000},"page":"783-787","source":"Crossref","is-referenced-by-count":10,"title":["Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study"],"prefix":"10.1515","volume":"32","author":[{"given":"Wenny Putri","family":"Nilamsari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy , Airlangga University , Surabaya , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fajar","family":"Rizqi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy , Airlangga University , Surabaya , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasya Olga","family":"Regina","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy , Airlangga University , Surabaya , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prastuti Asta","family":"Wulaningrum","sequence":"additional","affiliation":[{"name":"Department of Pulmonology , Dr. Soetomo Teaching Hospital , Surabaya , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umi","family":"Fatmawati","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Dr. Soetomo Teaching Hospital , Surabaya , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_001","unstructured":"World Health Organization. Global Tuberculosis Reports. Geneva: World Health Organization; 2019."},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_002","doi-asserted-by":"crossref","unstructured":"Gunther, G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med 2014;14:279\u201385. https:\/\/doi.org\/10.7861\/clinmedicine.14-3-279.","DOI":"10.7861\/clinmedicine.14-3-279"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_003","doi-asserted-by":"crossref","unstructured":"Sinshaw, Y, Alemu, S, Fekadu, A, Gizachew, M. Successful TB treatment outcome and its associated factors among TB\/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional study. BMC Infect Dis 2017;17:1\u20139. https:\/\/doi.org\/10.1186\/s12879-017-2238-7.","DOI":"10.1186\/s12879-017-2238-7"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_004","doi-asserted-by":"crossref","unstructured":"Skrahina, A, Hurevich, H, Zalutskaya, A, Sahalchyk, E, Astrauko, A, van Gemert, W, et al.. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J2012;39:1425\u201331. https:\/\/doi.org\/10.1183\/09031936.00145411.","DOI":"10.1183\/09031936.00145411"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_005","doi-asserted-by":"crossref","unstructured":"El-Shabrawy, M, El-Shafei, Dalia, A. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate. Egypt J Chest Dis Tuberc 2016;66:145\u201352. https:\/\/doi.org\/10.1016\/j.ejcdt.2015.11.002.","DOI":"10.1016\/j.ejcdt.2015.11.002"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_006","doi-asserted-by":"crossref","unstructured":"Mulu, W, Mekkonnen, D, Yimer, M, Admassu, A, Abera, B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci 2015;15:368. https:\/\/doi.org\/10.4314\/ahs.v15i2.9.","DOI":"10.4314\/ahs.v15i2.9"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_007","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014."},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_008","doi-asserted-by":"crossref","unstructured":"Palomino, JC, Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 2014;3:317\u201340. https:\/\/doi.org\/10.3390\/antibiotics3030317.","DOI":"10.3390\/antibiotics3030317"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_009","doi-asserted-by":"crossref","unstructured":"Salem, BC, Slim, R, Fathallah, N, Hmouda, H. Drug-induced hyperuricaemia and gout. Rheumatology 2017;56:679\u201388. https:\/\/doi.org\/10.1093\/rheumatology\/kew293.","DOI":"10.1093\/rheumatology\/kew293"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_010","doi-asserted-by":"crossref","unstructured":"Pokam, T, Enoh JE, BD, Eyo, AAO, Umoh, NO, Guemdjom, PW. Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon. Int J Mycobacteriol 2018;7:89\u201391.","DOI":"10.4103\/ijmy.ijmy_161_17"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_011","doi-asserted-by":"crossref","unstructured":"Louthrenoo, W, Hongsongkiat, S, Kasitanon, N, Wangkaew, S, Jatuworapruk, K. Effect of antituberculous drugs on serum uric acid and urine uric acid excretion. J Clin Rheumatol 2015;21:346\u20138. https:\/\/doi.org\/10.1097\/rhu.0000000000000297.","DOI":"10.1097\/RHU.0000000000000297"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_012","doi-asserted-by":"crossref","unstructured":"Zhang, Y, Wu, S, Xia, Y, Wang, N, Zhou, L, Wang, J, et al.. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an Ambispective Cohort Study. Med Sci Monit 2017;23:2348. https:\/\/doi.org\/10.12659\/msm.904682.","DOI":"10.12659\/MSM.904682"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_013","unstructured":"Sigdel, M, Dhakal, SR, Kandel, P, Maharjhan, N, Khan, GM. A study of adverse drug reactions caused by second line anti-tubercular drugs used in Nepal. Int J Health Sci Res 2016;6:201\u20138."},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_014","doi-asserted-by":"crossref","unstructured":"Francis, SP, Katz, J, Fanning, KD, Harris, KA, Nicholas, BD, Lacy, M, et al.. A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity. J Neurosci 2013;33:3079\u201393. https:\/\/doi.org\/10.1523\/JNEUROSCI.3430-12.2013.","DOI":"10.1523\/JNEUROSCI.3430-12.2013"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_015","doi-asserted-by":"crossref","unstructured":"Jiang, M, Karasawa, T, Steyger, PS. Aminoglycoside-induced cochleotoxicity: a review. Front Cell Neurosci 2017;11:308. https:\/\/doi.org\/10.3389\/fncel.2017.00308.","DOI":"10.3389\/fncel.2017.00308"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_016","doi-asserted-by":"crossref","unstructured":"Zhao, L, Young, WY, Li, R, Wang, Q, Qian, Y, Guan, MX. Clinical evaluation and sequence analysis of the complete mitochondrial genome of three Chinese patients with hearing impairment associated with the 12S rRNA T1095C mutation. Biochem Biophys Res Commun 2004;325:1503\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2004.10.199.","DOI":"10.1016\/j.bbrc.2004.10.199"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_017","doi-asserted-by":"crossref","unstructured":"Shibeshi, W, Sheth, AN, Admasu, A, Berha, AB, Negash, Z, Yimer, G. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. BMC Pharmacol Toxicol 2019;20:1\u201310. https:\/\/doi.org\/10.1186\/s40360-019-0313-y.","DOI":"10.1186\/s40360-019-0313-y"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_018","doi-asserted-by":"crossref","unstructured":"Modongo, C, Pasipanodya, JG, Zetola, NM, Williams, SM, Sirugo, G, Gumbo, T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 2015;59:6337\u201343. https:\/\/doi.org\/10.1128\/aac.01050-15.","DOI":"10.1128\/AAC.01050-15"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_019","doi-asserted-by":"crossref","unstructured":"El-Din, MAT, Halim, HAA-E, El-Tantawy, AM. Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009. Egypt J Chest Dis Tubercul 2015;64:657\u201364. https:\/\/doi.org\/10.1016\/j.ejcdt.2015.05.011.","DOI":"10.1016\/j.ejcdt.2015.05.011"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_020","doi-asserted-by":"crossref","unstructured":"Ahmad, N, Javaid, A, Syed Sulaiman, SA, Afridi, AK, Zainab, Khan, AH. Occurrence, management, and risk factors for adverse drug reactions in multidrug resistant tuberculosis patients. Am J Therapeut 2016;1\u20138. https:\/\/doi.org\/10.1097\/mjt.0000000000000421.","DOI":"10.1097\/MJT.0000000000000421"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_021","doi-asserted-by":"crossref","unstructured":"Shin, S, Furin, J, Alcantara, F. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004;125:974\u201380. https:\/\/doi.org\/10.1378\/chest.125.3.974.","DOI":"10.1378\/chest.125.3.974"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_022","doi-asserted-by":"crossref","unstructured":"Pham, P-CT, Pham, P-AT, Pham, SV, Pham, P-TT, Pham, P-MT, Pham, P-TT. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovascular Dis 2014;7:219. https:\/\/doi.org\/10.2147\/ijnrd.s42054.","DOI":"10.2147\/IJNRD.S42054"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_023","doi-asserted-by":"crossref","unstructured":"Magno, AL, Ward, BK, Ratajczak, T. E calcium sensing receptor: a molecular perspective. Endocr Rev 2011;32:3\u201330. https:\/\/doi.org\/10.1210\/er.2009-0043.","DOI":"10.1210\/er.2009-0043"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_024","doi-asserted-by":"crossref","unstructured":"Wang, Y, Chen, H, Huang, Z, McNeil, EB, Lu, X, Chongsuvivatwong, V. Drug non-adherence and reasons among multidrug-resistant tuberculosis patients in Guizhou, China: a cross-sectional study. Patient Prefer Adherence 2019;13:1641\u201353. https:\/\/doi.org\/10.2147\/ppa.s219920.","DOI":"10.2147\/PPA.S219920"},{"key":"2025121209024955831_j_jbcpp-2020-0447_ref_025","doi-asserted-by":"crossref","unstructured":"Van\u2019t Boveneind-Vrubleuskaya, N, Daskapan, A, Kosterink, JGW, van der Werf, TS, van den Hof, S, Alffenaar, J-WC. Predictors of prolonged TB treatment in a Dutch outpatient setting. PLoS ONE 2016;11:e0166030. https:\/\/doi.org\/10.1371\/journal.pone.0166030.","DOI":"10.1371\/journal.pone.0166030"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0447\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0447\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:27:35Z","timestamp":1765538855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2020-0447\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,25]]},"published-print":{"date-parts":[[2021,6,25]]}},"alternative-id":["10.1515\/jbcpp-2020-0447"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2020-0447","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}